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AbstrACt 
Introduction For non-ST-segment elevation acute 
coronary syndrome (NSTEACS) there is a gap between 
the use of class I guideline recommended therapies and 
clinical practice. The Global Registry of Acute Coronary 
Events (GRACE) risk score is recommended in international 
guidelines for the risk stratification of NSTEACS, but its 
impact on adherence to guideline-indicated treatments 
and reducing adverse clinical outcomes is unknown. The 
objective of the UK GRACE Risk Score Intervention Study 
(UKGRIS) trial is to assess the effectiveness of the GRACE 
risk score tool and associated treatment recommendations 
on the use of guideline-indicated care and clinical 
outcomes.
Methods and analysis The UKGRIS, a parallel-group 
cluster randomised registry-based controlled trial, will 
allocate hospitals in a 1:1 ratio to manage NSTEACS by 
standard care or according to the GRACE risk score and 
associated international guidelines. UKGRIS will recruit 
a minimum of 3000 patients from at least 30 English 
National Health Service hospitals and collect healthcare 
data from national electronic health records. The co-
primary endpoints are the use of guideline-indicated 
therapies, and the composite of cardiovascular death, 
non-fatal myocardial infarction, new onset heart failure 
hospitalisation or cardiovascular readmission at 12 months. 
Secondary endpoints include duration of inpatient hospital 
stay over 12 months, EQ-5D-5L responses and utilities, 
unscheduled revascularisation and the components of the 
composite endpoint over 12 months follow-up.
Ethics and dissemination The study has ethical 
approval (North East - Tyne & Wear South Research Ethics 
Committee reference: 14/NE/1180). Findings will be 
announced at relevant conferences and published in peer-
reviewed journals in line with the funder’s open access 
policy.
trial registration number ISRCTN29731761; Pre-results.
bACkground
Non-ST-segment elevation acute coronary 
syndrome (NSTEACS) is a leading cause of 
disability, hospitalisation and death, and has 
major impacts on health economies.1 Since 
NSTEACS prognosis is determined by both 
baseline clinical risk and the use of evidence-
based therapies, appropriately- stratified and 
effectively-delivered NSTEACS care has the 
strengths and limitations of this study
 ► UK GRACE Risk Score Intervention Study is a trial of 
patient management according to a risk model to 
reduce adverse patient clinical outcomes. This as-
sessment of the effectiveness of risk stratification 
uses level one scientific methods.
 ► The design, intervention, patient population and 
outcomes are sufficiently similar to existing and 
planned international trials to facilitate individual 
participant data meta-analysis.
 ► The trial will use nationwide patient–level health 
records to enhance baseline and outcomes infor-
mation derived from clinical records and patient 
questionnaires.
 ► Compliance with the assigned intervention at the 
cluster level requires monitoring, and clinical events 
cannot be centrally adjudicated, as they arise from 
electronic health records. As such, this is a pragmat-
ic trial with results generalisable to the ‘real world’ 
clinical environment.
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potential to achieve cost-effective patient-centred treat-
ment and improve clinical outcomes.2–5 For NSTEACS, 
however, there is a risk-treatment paradox whereby lower 
rather than higher risk patients are more likely to receive 
an invasive coronary strategy and more aggressive phar-
macotherapies.6–8 The paradox is due to a number of 
factors including inaccurate and subjective risk assess-
ment, under-recognition of the potential treatment bene-
fits that higher risk cohorts may have, and cumulative 
missed care opportunities.9–12 
Despite recommendation by national agencies such as 
the National Institute for Health and Care Excellence, 
the European Society of Cardiology and the American 
College of Cardiology (ACC)/American Heart Associa-
tion (AHA),2–5 scoring systems which objectively charac-
terise cardiovascular risk are not systematically applied to 
the management of NSTEACS.12 The Global Registry of 
Acute Coronary Events (GRACE) risk score tool is specif-
ically designed for the risk stratification of patients with 
acute coronary syndrome (ACS), is aligned to treatment 
recommendations and, compared with other ACS risk 
scores, has superior discriminative performance.13 14 It 
was developed in an international registry programme 
to predict in-hospital and 6 month death or non-fatal 
myocardial infarction (MI) in a broad spectrum of ACS 
patients, and has since been derived and validated for 
these outcomes in over 42 000 patients with external vali-
dation in other cohorts.15 16 For clinical use, a simplified 
model was derived that predicts the risk of death alone, 
and the composite outcome of death or non-fatal MI, 
based on eight variables (age, heart rate, systolic blood 
pressure, Killip class, creatinine concentration, elevated 
biomarkers of myocardial injury, cardiac arrest on admis-
sion and ST-segment deviation). These factors conveyed 
more than 90% of the total risk and had a c-statistic of 
0.81 for predicting death and 0.73 for predicting death or 
non-fatal MI from admission to 6 months after discharge.17 
The GRACE risk score also shows good discriminatory 
performance for mortality at up to 2 years following 
discharge from hospital with ACS.18 The GRACE risk score 
has been updated (http://www. outcomes- umassmed. 
org/ grace/) and shows good predictive accuracy of 1 year 
and 3 year mortality across a spectrum of ACS types.19 20
While evidence from registry data suggests that more 
comprehensive NSTEACS treatment is associated with 
improved outcome, there are no studies that have tested 
whether the prospective use of the GRACE risk score tool 
improves adherence to guideline recommendations for 
the management of NSTEACS and reduces adverse clin-
ical outcomes.8 21 Complex behavioural interventions, 
such as the use of a risk score tool, have several interacting 
components. Typically, they present difficulties in (1) the 
standardisation of the design and delivery of the interven-
tion, (2) their sensitivity to local context, (3) the organ-
isational difficulty of applying experimental methods to 
service change and (4) the length and complexity of the 
causal chains linking the intervention with outcomes.22 
It is not surprising, therefore, that some randomised 
controlled trials (RCTs) of complex interventions have 
failed to show improvements in outcomes, while others 
have succeeded.23 24
The UK is unique in that (1) national data are systemat-
ically and routinely collected for the populace regarding 
hospital healthcare utilisation and mortality, and for those 
admitted to hospitals with ACS information about cardiac 
investigations, pharmacotherapies and invasive coronary 
procedures25 and (2) the National Institute for Health 
Research through its Clinical Research Network supports 
National Health Service (NHS) hospitals to undertake 
research at scale. Thus, we aim to harness this national 
platform to undertake an efficient, pragmatic RCT to 
test the hypothesis that the use of the GRACE risk score 
tool will increase guideline-recommended treatment and 
decrease clinical events in NSTEACS patients.
MEthods And dEsIgn
objectives
The UK GRACE Risk Score Intervention Study (UKGRIS; 
ISRCTN29731761, online supplementary file 1) will test 
the effectiveness of the use of the GRACE risk score tool 
by healthcare professionals on the delivery of guideline 
recommended care and clinical outcomes among patients 
hospitalised with NSTEACS. Co-primary objectives of the 
trial are:
1. To determine whether implementing the GRACE risk 
score increases the use of class I guideline-indicated 
therapies for the management of NSTEACS within the 
guideline recommended time, compared with current 
standard care;
2. To determine whether implementing the GRACE risk 
score reduces the composite endpoints of cardiovas-
cular death, non-fatal MI, new onset heart failure and 
cardiovascular readmission at 12 months, compared 
with current standard care.
Secondary objectives are to determine whether imple-
menting the GRACE risk score has an impact on:
1. Health-related quality of life at 12 months post-regis-
tration (measured by the EQ-5D-5L questionnaire);
2. Occurrence of unscheduled coronary revascularisa-
tion within the 12 months of initial presentation;
3. Duration of hospital stay within 12 months of initial 
presentation;
4. The individual components of the co-primary compos-
ite endpoint within 12 months.
trial design
This publication describes V.3.0 of the UKGRIS protocol, 
dated 12th November 2018.
UKGRIS is a two-arm 1:1 parallel-group, open-label, 
multicentre, cluster-randomised, controlled regis-
try-based superiority trial. UK hospitals are eligible to 
participate in UKGRIS if they are acute NHS hospitals 
participating in the Myocardial Ischaemia National Audit 
Project and willing to implement the GRACE risk score 
tool if randomised to that arm. Hospitals are ineligible 
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if they are already routinely using the GRACE risk score 
tool prior to randomisation.
Randomisation and blinding
Eligible hospitals (clusters) will be centrally randomised 
by the Leeds Clinical Trials Research Unit (CTRU) 
1:1 to either GRACE risk score guided management 
or standard care using minimisation with a random 
element, aiming to ensure the cluster composition of 
each study arm is similar with respect to cluster-specific 
volume of patients hospitalised with ACS and primary 
percutaneous coronary intervention (PCI) capability. 
Site staff will not be blind to their assigned interven-
tion, nor will recruited participants be blind to the 
intervention assigned to that site. Once a hospital has 
been randomised to the use of the GRACE risk score 
tool or to standard care, informed of their allocation 
and completed site initiation as required for their arm, 
a run-in phase will take place. During this time (up to 
3 months for each site), the data collection and quality 
will be evaluated and the frequency of GRACE applica-
tion in the intervention arm sites will be measured, as 
patients are recruited. (figure 1).
Eligibility criteria
Participants will be recruited from the randomised 
hospital to which they present. Eligibility criteria are delib-
erately broad and pragmatic: participants must be aged 
18 years and above, hospitalised with NSTEACS (either 
non-ST-elevation myocardial infarction (NSTEMI) or 
unstable angina) and provide written informed consent 
(box 1). They must not present with ST-elevation myocar-
dial infarction, or with NSTEACS precipitated by a clear 
non-cardiovascular cause (for example, motor vehicle 
accident, trauma, severe gastrointestinal bleeding, 
Figure 1 GRACE site recruitment and study run-in. CTRU, 
Leeds Clinical Trials Research Unit; GRACE, Global Registry 
of Acute Coronary Events. 
box 1 Full eligibility criteria for participants
Participant inclusion criteria
1. Aged≥18 years
2. Symptoms consistent with acute cardiac ischaemia for  >10 mins 
within 24 hours of presentation to hospital plus either or both of:
 ► one of (a,b,c);
 ► at least two of the High Risk Features (d)
(a) ECG changes:
 ► Transient ST-segment elevation of 0.5 mm in two or more contig-
uous leads;
 ► ST-segment depression of 0.5 mm in two or more contiguous leads;
 ► New T wave inversion of 1 mm in two or more contiguous leads;
 ► New Q waves (1/3 height of R wave or >0.04 s);
 ► New R wave>S wave in lead V1; or,
 ► New left bundle branch block
(b) Elevated cardiac biomarkers:
 ► Troponin T or I above the upper reference limit (URL);
 ► creatine kinase-muscle/brain (CK-MB) 2x URL; or,
 ► If there is no CK-MB available, then total CK greater than the local 
URL
(c) Documented coronary artery disease:
 ► History of myocardial infarction (MI) or angina;
 ► Congestive cardiac failure due to ischaemia;
 ► Resuscitated sudden cardiac death;
 ► Prior or new positive stress test with or without imaging;
 ► Prior or new, cardiac catheterisation, percutaneous coronary artery 
intervention or coronary artery bypass graft surgery documenting 
coronary artery disease
(d) At least two of the following High Risk features:
 ► Haemodynamic compromise (systolic blood pressure <90 mmHg 
and heart rate >100 bpm)
 ► Left ventricular systolic dysfunction (left ventricular ejection fraction 
<0.40);
 ► Presence of known diabetes mellitus
 ► Documentation of chronic kidney disease (estimated glomerular fil-
tration rate <60mls/min/m2)
3. Willing and able to provide written informed consent
Participant exclusion criteria
1. Patients presenting at hospital due to an acute ST-segment eleva-
tion myocardial infarction
2. Patients presenting at hospital with an acute coronary syndrome   
accompanied with, or precipitate by significant comorbidity for 
example, motor vehicle accident, trauma, severe gastrointestinal 
bleeding
3. Perioperative or periprocedural MI
4. Patients already recruited into the study
5. Patients not living in the UK
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perioperative/periprocedural myocardial infarction) or 
be previously enrolled in the trial. 
The site Principal Investigator or a delegated member 
of the clinical research team will undertake the informed 
consent process. The participant will be approached 
within 12 hours of hospital admission (ideally in the 
emergency department or acute admission ward, which-
ever is closer to the time of hospitalisation), allowed time 
to consider the information and ask questions before 
deciding whether to participate. An optional oral consent 
pathway is available where participants will be provided 
with a shortened document describing the UKGRIS trial 
and after discussing the trial with the research nurse, can 
verbally consent to commence the care assigned to the 
admitting hospital. In hospitals allocated to GRACE, risk 
scores will be calculated and treatment recommenda-
tions made. Thereafter, the patient will be approached 
for full written informed consent. Participants who give 
oral consent at this point will be registered and complete 
the self-reported questionnaire and frailty score. Partici-
pants who give oral consent and refuse written informed 
consent will be excluded, and completed case record 
forms (CRFs) destroyed.
The informed consent process will request consent 
for data from all registeredpatients to be included in 
planned collaborative international analysis to investigate 
the GRACE risk score internationally, based on a planned 
individual patient data (IPD) meta-analysis of similar trials 
in Australia and Canada.26 The right of the participant to 
refuse participation without prejudice to future care will 
be respected, as will be the right to withdraw consent to 
further participation.
Efforts to ensure adequate and broad recruitment of 
all eligible patients in both arms through site research 
staff include: designation of a site ‘champion’, respon-
sible for ensuring all staff are aware of the study and 
regular contacts to identify barriers to recruitment and/
or trial compliance, trial posters, a twitter account (@
UKGRIS_Trial).
trial status
The first site opened to recruitment on 13th February, 
2017, and the first patient was recruited on 13th March, 
2017. At the time of manuscript submission, 39 hospitals 
had been randomised to a study arm (of which 30 have 
registered at least one patient), and 2515 patients had 
consented to take part. Recruitment is expected to end 
on 31st December, 2019, with end of follow-up ending on 
31st December, 2020, and completion of analysis by 30th 
June, 2021.
governance
The trial is funded by the British Heart Foundation 
(grant reference CS/16/2/32145) and the sponsor is the 
University of Leeds (Leeds, UK). Neither the sponsor nor 
the funders are involved with study design, data collec-
tion, management, analysis or interpretation, nor will they 
have any influence on decisions relating to publication. 
The funders may review draft publications, but all final 
decisions will rest with the authors. The sponsor reserves 
the right to conduct periodic source data verification to 
monitor the integrity of the trial.
Interventions
GRACE risk score tool
Consenting participants recruited from hospitals in the 
intervention arm will receive care determined by staff 
trained to use the GRACE risk score tool and provided 
with a paper scoring table. Each consenting participant 
will have their risk score and corresponding 6 month 
mortality risk estimated by the appointed healthcare 
professional within 12 hours of hospitalisation. GRACE 
risk scores are categorised as ‘low’ (0 to 108), ‘interme-
diate’ (109 to 140) or ‘high’ (≥141), and the risk score 
nomogram (figure 2) will list recommended therapies 
(including pharmacological, invasive, non-invasive and 
behavioural interventions and tests) for patients based 
on their risk category (figure 3). At the same time as 
the GRACE risk score is calculated, sites will complete 
the CRUSADE bleeding risk score (Can Rapid risk strat-
ification of Unstable angina patients Suppress ADverse 
outcomes with Early implementation of the ACC/AHA 
Guidelines).27 Both GRACE and CRUSADE will be 
completed using pen and paper scoring tables provided 
by the CTRU, online scoring applications and websites 
will not be used. Figure 2 illustrates the GRACE risk 
score nomogram as used in UKGRIS, while figure 3 illus-
trates the resulting recommendations arising from the 
scores obtained. Sites are invited to justify their deci-
sions in declining to follow a recommendation on the 
grounds of contraindication. As part of the site initiation 
process, intervention sites will be informed as to how to 
complete the GRACE risk score paper nomogram, and 
follow its resulting recommendations. Sites will be moni-
tored by telephone interviews with the ‘site champion’ 
throughout recruitment to ensure that GRACE and 
CRUSADE scoring is still routinely used for managing 
patients with NSTEACS. If GRACE sites stop routinely 
using the GRACE and CRUSADE risk scores, they will be 
asked to resume their use, and to cease recruitment to the 
UKGRIS trial if they fail to do so.
Standard care
Hospitals randomised to standard care will treat patients 
according to local practice (without using the GRACE 
risk score tool and associated clinical prompts) (figure 1). 
Sites will be monitored by telephone interviews with 
the ‘site champion’ throughout recruitment to ensure 
that processes for managing patients with NSTEACS 
are unchanged and that the management according 
to the GRACE risk score has not been systematically 
implemented due to a change in hospital policy. Stan-
dard care-assigned sites should not be routinely using 
the GRACE risk score nor the CRUSADE bleeding risk 
score to manage NSTEACS patients while taking part in 
the trial. Standard care sites implementing either scoring 
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system during the study (as identified during regular 
site monitoring updates) will be asked to cease use and 
will stop recruitment to the UKGRIS trial if routine use 
continues.
outcome measures
There are two co-primary endpoints: (i) the uptake of class 
I guideline-indicated therapies (specifically, the 11 listed 
in online supplementary file 2) and (ii) the composite 
of cardiovascular death, non-fatal myocardial infarction, 
hospitalisation for new onset heart failure or cardiovas-
cular readmission, at 12 months (table 1, with subse-
quently derived outcome measures in table 2). Secondary 
endpoints are total duration of inpatient stay, quality of 
life based on EQ-5D-5L28 responses and utilities, unsched-
uled coronary revascularisation and the components of 
the composite endpoint over 12 months follow-up.
data collection
Potential participants who do not take part (either inel-
igible or non-consenting) will be recorded on non-reg-
istration logs recording age, sex, ethnicity and reason 
for patient non-registration. These will be collected by 
local investigators and returned to the CTRU. Baseline 
variables for registered participants will be collected on 
paper CRFs by site staff, who will keep copies and return 
originals to the CTRU (except for consent forms which 
are kept at site and copies sent to the CTRU). GRACE 
and CRUSADE risk scores will be estimated for each 
participant at each participating hospital site randomised 
to use the GRACE risk score tool and recorded on CRFs. 
Since the paper nomogram approach is also being used 
in similar international trials, scoring via mobile phone 
apps or web-based calculators will not be permitted. 
Details of medications and tests prescribed and received 
during hospitalisation will be recorded. At baseline, the 
participants’ Edmonton frailty score29 will be assessed 
and all participants will complete the EQ-5D-5L question-
naire. At 12 months, surviving participants will be asked 
to complete and return a further EQ-5D-5L by post.
Follow-up data for hospital healthcare utilisation, and 
dates and causes of death will be collected using multi-
source national electronic health records (EHRs). This 
Figure 2 GRACE and CRUSADE risk scoring paper chart (completed by intervention sites only, and not distributed to control 
arm sites). CRUSADE, Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early 
implementation of the ACC/AHA Guidelines; CTRU, Leeds Clinical Trials Research Unit; eGFR, estimated glomerular filtration 
rate; GRACE, Global Registry of Acute Coronary Events; Hct, haematocrit; SBP, systolic blood pressure; UKGRIS, UK GRACE 
Risk Score Intervention Study. 
H
ospital M
edical Library. Protected by copyright.
 o
n
 Septem
ber 24, 2019 at Assistant Librarian St Jam
es`s
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-032165 on 5 September 2019. Downloaded from 
6 Everett CC, et al. BMJ Open 2019;9:e032165. doi:10.1136/bmjopen-2019-032165
Open access 
will include data capture from the National Institute for 
Cardiovascular Outcomes Research25 suite of nationwide 
cardiovascular registries,30 31 Hospital Episode Statistics,32 
Office for National Statistics and the National Audit of 
Cardiac Rehabilitation database.33 To obtain records, the 
CTRU will provide the patient identifiers to the respon-
sible organisations (with patient consent obtained for this 
data transfer) who will link the identifiers to their records 
according to their own deterministic algorithms and 
return to the CTRU the relevant records via secure file 
transfer or data interrogation system. The occurrence of 
clinical events will not be centrally adjudicated, since the 
EHR do not include access to the detailed hospital notes. 
We will investigate the effect of discrepancies between 
the EHR and the data reported on the CRFs, on the trial 
results in a sensitivity analysis.
Data received via CRFs will be entered onto a dedicated 
CTRU database (MACRO, InferMed) which will include 
validations to identify missing or discrepant data. The 
trial statistician will download accumulated data to iden-
tify discrepant data items for investigation. Data received 
via EHR will be automatically uploaded to the MACRO 
database via a data import system.
statistical methods
Sample size
A minimum of 30 clusters, each recruiting 100 partic-
ipants (ie, 3000 in total) will give 80% power to detect 
clinically relevant differences in the co-primary endpoints 
with two-sided 5% significance tests (see sections 7.2.1 
and 7.2.3 of34). For the proportion of class I guideline-rec-
ommended therapies implemented, this assumes 95%35 
of recommended therapies implemented in the control 
arm and will detect an absolute increase of 3% to 98% in 
the GRACE arm, with an assumed coefficient of variation 
(CV) in cluster outcomes of 0.02. For time to first cardiac 
outcome, a fixed recruitment of 15 clusters of 100 patients 
per arm gives 80% power to detect a difference in 12 month 
rates of 13% and 10.4% between standard care and GRACE 
arms, assuming a mean follow-up of 27 months and CV of 
cluster event rates of 0.05. Both endpoints require 14 clus-
ters of 100 patients in each arm to have 80% power, though 
Figure 3 Associated guideline recommended therapies for GRACE risk score categories (completed by intervention sites only, 
not distributed to control arm sites). ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CTRU, Leeds 
Clinical Trials Research Unit; GRACE, Global Registry of Acute Coronary Events; LV, left ventricular; MI, myocardial infarction; 
NICE, National Institute for Health and Care Excellence; NSTEACS, non-ST-segment elevation acute coronary syndrome; PCI, 
percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; UA, urinalysis; UF, unfractionated; UKGRIS, UK 
GRACE Risk Score Intervention Study. 
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no adjustment for multiple testing was made. Recruiting 
15 clusters per arm allows for attrition of 7% to 10%. For 
more details, see online supplementary file 3. Additional 
sites have been and will be opened to ensure that target 
recruitment is achieved, and to safeguard study power 
should these assumptions not be met.
Analysis methods
A full statistical analysis plan will be finalised prior to any 
comparative analyses, following the guidelines of Gamble 
et al.36 The statistical analysis plan will describe the deri-
vation of outcomes, define analysis populations and detail 
the analyses of each outcome measure. In brief, analyses 
will take the form of generalised linear models that include 
fixed effects for the minimisation/stratification factors and 
random effects for the recruiting hospitals (the random 
effects distribution with the best statistical fit will be used 
for analysis) to reflect the cluster-randomised nature of 
the trial (table 2). The derivation of the primary outcome 
Table 1 Schematic of assessments
TIME POINT*
Cluster
identification
Cluster 
allocation
Patient 
identification
Patient 
registration Post-allocation
-t3 -t2 -t1 0 tA tD 12 m
CLUSTER ENROLMENT:
  Eligibility screen X
  Essential documents X
  Randomisation X
  Site initiation X
PATIENT ENROLMENT:
  Eligibility X
  Informed consent X
  Registration X
INTERVENTIONS:
  GRACE/CRUSADE risk scoring 
(X) and subsequent care
X
  Standard care X
  ASSESSMENTS:
  Baseline assessments* X
  EQ-5D-5L X X
  Edmonton frailty score X
  Numbers of class I guideline 
indicated therapies
X
  Numbers of therapies received X X
  Date of discharge X
  Final diagnosis X
  Medications prescribed acutely 
during hospital stay or on discharge
X
  In-hospital cardiovascular procedures X
  In-hospital outcomes X
  Other cardiac investigations and 
treatments
X
  Health advice given X
  Hospitalisations X
  Deaths X
  Unscheduled revascularisations X
*Time points: -t3, -t2, -t1 are three arbitrary time points that occur at any time (but in the given order) prior to individual patient enrolment at 
time 0. Post registration, tA and tD are the time points at which a participant is assessed according to the cluster-randomised strategy and 
discharged from hospital. Subsequent follow-up is at 12 months.
†Baseline assessments are: age, sex, ethnicity, height, weight, date and time of symptoms onset and admission to hospital, ECG ST-segment 
deviation, heart rate on admission, systolic blood pressure on admission, Killip class, diuretic usage, creatinine, troponin (date, time and 
elevated), cardiac arrest occurrence, haematocrit, peripheral vascular disease, diabetes mellitus, congestive cardiac failure.
CRUSADE, Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA 
Guidelines; GRACE, Global Registry of Acute Coronary Events. 
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measure is defined in online supplementary file 2. Addi-
tional exploratory subgroup analyses are planned for the 
primary endpoint: analysing guideline uptake according to 
intervention type (invasive, non-invasive, behavioural and 
pharmacotherapies); subgroup effects will investigate inter-
action between treatment arm and age, gender, diabetes, 
heart failure, initial hospital type, frailty, comorbidity and 
estimated bleeding risks, among others. Analyses will use 
the full analysis set comprising all registered participants 
analysed according to their randomised hospital as inten-
tion to treat (patients will only be excluded if informed 
consent was not given, or if participants request that their 
data not be used in any analysis). Further supporting 
randomisation-respecting efficacy analyses may be consid-
ered, in particular, a mediation analysis37 to estimate the 
net direct and net indirect effects of a non-NSTEACS final 
diagnosis on receiving class I guideline therapies. The 
statistical analysis plan will include an agreed strategy for 
imputing missing data items (using multiple imputation, 
where appropriate38 39), including handling incomplete 
EHR on cardiovascular registries and other data sources 
to determine whether absent records indicate no events.
Monitoring
Oversight of the trial will be the responsibility of the inde-
pendent Trial Steering Committee (TSC), comprising 
two independent cardiologists, an independent statis-
tician and one independent patient representative. An 
independent Data Monitoring and Ethics Committee 
(DMEC) will meet to review accumulating safety and 
compliance data from the UKGRIS trial. The members 
will comprise an independent statistician and three inde-
pendent cardiologists. There are no planned interim 
analyses of efficacy for the UKGRIS trial. The members 
of the Trial Management Group, the DMEC and the TSC 
are listed in online supplementary file 4.
Given that the intervention carries minimal risk to 
participants, serious and non-serious unrelated or 
expected adverse events will not be reported. Instead, 
participant primary and secondary outcomes at the time 
of discharge from hospital (or death if it occurs during 
hospitalisation) until 12 months will be reviewed by the 
DMEC at a site level using CRFs and EHRs. All related 
and unexpected serious adverse events occurring from 
the date of consent up to 3 months following admission 
will be sent to the CTRU within 24 hours of the clinical 
research staff becoming aware of the event. Changes 
to the protocol will be provided to the Research Ethics 
Committee for review. On receipt of favourable opinion, 
new versions of the protocol will be communicated to 
sites for implementation. Sites randomised to routinely 
Table 2 Definitions of UKGRIS outcome measures and primary analyses
Outcome measure Assessed at Analysis method
Co-primary
(1) Number of class I guideline indicated 
processes received per patient (see online 
supplementary file 2 for full description)
Discharge Logistic regression, modelling agreement between 
eligibility and receipt of process as function of treatment 
arm, including fixed effects for minimisation factors, 
random hospital effect and random patient effect.
(2) Time from registration until first occurrence of 
one of the following
* cardiac death,
* new onset heart failure,
* non-fatal MI, or
* cardiovascular hospitalisation
12 months post 
registration
Kaplan-Meier survival estimates; appropriate time-
to-event regression (eg, proportional hazards, 
flexible parametric model47) including fixed effects 
for minimisation factors and random hospital effect, 
(sensitivity analysis: also accounts for competing risks of 
non-cardiac death and withdrawal from follow-up.)
Secondary
(1) Health-related quality of life (EQ-5D-5L utility) 12 months post 
registration
Linear regression, (with data transformed, if necessary) 
including fixed effects for minimisation factors and 
baseline value with random hospital effect.
(2) Number of days in hospital within 12 months 12 months post 
registration
Linear regression (with data transformed, if necessary) 
including fixed effects for minimisation factors and 
random hospital effect.
(3) Time until first occurrence of each component 
of the composite co-primary endpoint (co-
primary (2)). Performed separately for each of the 
four components.
12 months post 
registration
Kaplan-Meier survival estimates; time-to-event regression 
including fixed effects for minimisation factors and 
random hospital effect, accounting for (sensitivity 
analysis: competing risks of non-cardiac death and 
withdrawal from follow-up.)
(4) Unscheduled revascularisations. Any 
admission (1=Yes, 0=No) for an unplanned PCI 
or CABG within 12 months of registration.
12 months post 
registration
Logistic regression, including fixed effects for 
minimisation factors with random hospital effect.
CABG, coronary artery bypass graft; MI, myocardial infarction; PCI, percutaneous coronary intervention; UKGRIS, UK GRACE Risk Score 
Intervention Study. 
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employ the GRACE risk score tool will be able to note 
where particular guideline-recommended therapies are 
deemed not appropriate. All sites will be able to report 
that guideline-recommended invasive strategies are not 
appropriate.
Ethics and dissemination
A favourable opinion was provided by the North East - 
Tyne & Wear South Research Ethics Committee on 31st 
October, 2016, (reference 14/NE/1180). Trial results will 
be disseminated at relevant conferences and published 
in peer-reviewed journals. Authorship will be decided 
according to ICMJE guidelines as to qualifying contribu-
tions, and the primary results manuscript jointly drafted 
by the Chief Investigator and the trial methodologists 
before circulating to remaining co-authors.
Patient and public involvement
During the initial design stage, the applicants consulted 
the patient and public involvement group associated 
with the co-ordinating centre to inform the study design, 
particularly with regard to the participant burden, so as 
to reduce loss to follow-up. The Trial Steering Committee 
includes a patient representative. We have also consulted 
patient representatives as to the design of covering letters 
used in our 12 month mailed questionnaire follow-up.
dIsCussIon
International guidelines recommend the use of the 
GRACE risk score for stratification of patients hospitalised 
with NSTEACS such that they may receive evidence-based 
care according to their estimated risk of future ischaemic 
events.2 3 5 While observational studies have validated the 
GRACE risk score across diverse populations and for a 
range of clinical outcomes,40 and shown that a failure 
to follow NSTEMI guideline recommendations leads to 
excess mortality,41 there are no randomised data investi-
gating whether the routine use of the GRACE risk score 
tool improves NSTEACS care and reduces subsequent 
cardiovascular events.
The UKGRIS trial will determine whether the system-
atic use of the GRACE risk score increases the use of 
class I guideline-indicated therapies for the management 
of NSTEACS and reduces a composite cardiovascular 
endpoint at 12 months compared with current standard 
care. UKGRIS will encompass multisource national EHRs 
for data capture of the primary endpoints. Moreover, 
UKGRIS will form part of an international collaborative 
consortium and run in parallel with trials with harmonised 
protocols in Australia26 and Canada. While the UKGRIS 
study will focus on impacts on clinical- and cost-effective-
ness for a contemporary UK population, a harmonised 
protocol across the three international trials will facilitate 
IPD meta-analysis to improve precision of the estimated 
reduction in mortality and other cardiovascular events.
Optimising risk assessment of hospitalised NSTEACS 
may help reduce inequalities in the provision of care. 
Serving as a healthcare prompt at point of entry into the 
health service system, the GRACE risk score and associ-
ated international guideline recommendations for the 
management of NSTEACS may reduce the risk–treat-
ment paradox. Recent observational data suggest that the 
decline in mortality over time among NSTEMI patients 
was significantly associated with the use of an invasive 
coronary strategy and the wider application to higher risk 
cases,42 and the impact of guideline-indicated treatments 
for NSTEMI persists for many years. Extending this initia-
tive to undertreated higher risk NSTEACS may further 
improve clinical outcomes. Moreover, when compared 
with objective risk assessment, physician-estimated risk 
offers less discriminatory performance and is associated 
with lower rates of PCI among higher risk patients.14 43 44
UKGRIS follows the Medical Research Council frame-
work for the development and evaluation of complex 
behavioural interventions.45 A complex behavioural 
intervention aiming to change health behaviour contains 
several interacting components. For UKGRIS, the inter-
vention is the use of a risk score tool, reference to an inter-
nationally recommended algorithm for the management 
of NSTEACS and informing healthcare professionals of 
the results of the risk calculation and associated guide-
line-indications for treatment. Moreover, the GRACE risk 
score comprises components such as age and blood pres-
sure which are predictors of adverse outcomes; a clinician 
may, consciously or otherwise, base care management 
decisions on the presence of these factors, without 
resorting to a formalised risk scoring system. Studies of 
complex behavioural interventions may be criticised 
because they do not determine how and why interven-
tions work.46 Thus, UKGRIS will collect information as 
to why guideline recommendations are not followed and 
data concerning frailty (a possible justification for non-re-
ceipt of evidence-based care).
UKGRIS will collect clinical data from a range of 
national EHRs. Limitations inherent in this approach 
include non-capture of all data relating to the disease 
(data missing by design), missing and corrupt data as 
recorded in routine national databases, time lag of data 
acquisition, non-consent for data capture, contamination 
and lack of fidelity. UKGRIS aims to be a streamlined and 
pragmatical registry-based trial, answering finite ques-
tions efficiently. As such, a priori endpoints were designed 
around the availability of data (for example, hospitalised 
rather than all new heart failure diagnoses), and key 
safety outcomes (mortality) will be requested from the 
UK Office for National Statistics. Missing and corrupt 
data are infrequent in national administrative database 
and for clinical registries we will augment data collection 
through the CRFs. We assume data anomalies will be 
equally balanced between intervention and control arms 
through randomisation. To reduce the potential for with-
in-site contamination of the intervention, UKGRIS will 
randomise to the intervention at the hospital level, and 
treatment arm fidelity will be monitored and maintained 
by regular contact with each site. We should acknowledge 
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that clinicians at all sites may improve their individual 
guideline implementation rates due to the Hawthorne 
effect of taking part in the study. Existing registry data for 
patients not taking part may indicate how GRACE trial 
performance differs from ‘real-world’ practice.
ConClusIons
Following hospital presentation with NSTEACS, subse-
quent CV morbidity and mortality rates are high and there 
is a gap between international recommendations for treat-
ment and clinical practice. UKGRIS, a registry-based clus-
ter-randomised controlled trial will determine whether 
an integrated behavioural intervention (the routine use 
of the GRACE risk score tool and associated management 
guidance) increases the use of class I guideline-indicated 
therapies for the management of NSTEACS and reduces 
a composite cardiovascular endpoint at 12 months, 
compared with current standard care. Though UKGRIS 
will, on its own, provide evidence of the value of GRACE 
risk implementation for NSTEACS cases in the UK, the 
opportunity for an international IPD meta-analysis means 
that the benefits of the UKGRIS study will reach much 
further.
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